CAPTRUST Financial Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-442
Closed -$26.7K 2819
2023
Q3
$26.7K Sell
442
-33
-7% -$3.1K ﹤0.01% 2514
2023
Q2
$48.4K Buy
475
+17
+4% +$2.34K ﹤0.01% 2431
2023
Q1
$81K Buy
458
+12
+3% +$4.02K ﹤0.01% 2176
2022
Q4
$172K Buy
+446
New +$169K ﹤0.01% 1968
2022
Q3
Sell
-29
Closed -$9K 4177
2022
Q2
$9K Sell
29
-44
-60% -$15.4K ﹤0.01% 3825
2022
Q1
$32K Buy
73
+32
+78% +$13.1K ﹤0.01% 3108
2021
Q4
$18K Sell
41
-7
-15% -$3.52K ﹤0.01% 3379
2021
Q3
$27K Buy
+48
New +$24.1K ﹤0.01% 2976
2021
Q2
Sell
-83
Closed -$65K 4680
2021
Q1
$65K Hold
83
﹤0.01% 2254
2020
Q4
$45K Buy
83
+14
+20% +$7.34K ﹤0.01% 1880
2020
Q3
$32K Hold
69
﹤0.01% 1783
2020
Q2
$44K Buy
+69
New +$38.1K ﹤0.01% 1666
2019
Q4
Sell
-125
Closed -$82K 1859
2019
Q3
$82K Hold
125
﹤0.01% 836
2019
Q2
$97K Sell
125
-11
-8% -$7.73K ﹤0.01% 775
2019
Q1
$96K Hold
136
﹤0.01% 714
2018
Q4
$64K Buy
136
+39
+40% +$25.2K ﹤0.01% 709
2018
Q3
$84K Buy
97
+28
+41% +$20.2K ﹤0.01% 654
2018
Q2
$48K Buy
69
+66
+2,200% +$33.5K ﹤0.01% 693
2018
Q1
$1K Buy
+3
New +$1.46K ﹤0.01% 1300

Other funds holding TVRD

CAPTRUST Financial Advisors's TVRD Position: Q4 2023 in Review

CAPTRUST Financial Advisors sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 442 shares — an estimated $26.7K sold.

CAPTRUST Financial Advisors first reported a position in TVRD in Q1 2018 and held it in 19 quarters. The position peaked at $172K in Q4 2022. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • CAPTRUST Financial Advisors reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 442 Tvardi Therapeutics shares in Q4 2023, an estimated $26.7K.
  • CAPTRUST Financial Advisors first reported a position in Tvardi Therapeutics in Q1 2018 and held it in 19 quarters.
  • CAPTRUST Financial Advisors's Tvardi Therapeutics position peaked at $172K in Q4 2022.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.